The drug Xofigo (radium-223 dichloride) is a drug that targets metastatic lesions of bone tissue, destroying these focal lesions by exposure to alpha radiation. Due to their characteristic properties of mass and charge, alpha particles release high energy in an extremely short path (less than 100 microns) – this feature makes them less permeable to the environment (thus, there is less damage to healthy bone marrow tissue located near metastatic foci and in the patient experiences far fewer side effects). This therapy is more toxic to metastatic lesions compared to gamma or beta radiation.
Active ingredient: radium chloride [223Ra]
Prescription medicine